Accelerating the implementation of digital transformation has gradually become the focus of domestic and foreign pharmaceutical companies

【Pharmaceutical Network Market Analysis】For a long time, the concept of "patient-centered" has always run through the development of
modern medical and health industry.
It is worth noting that the development of Internet medical care has further made this concept a reality
.
Digital capabilities have gradually become an important starting point
for pharmaceutical companies to truly achieve patient access and patient management.
At present, a large number of domestic and foreign pharmaceutical companies are actively cooperating
with digital enterprises and platforms.
It is reported that during the recent Expo, many pharmaceutical companies have signed contracts with Ali Health and launched new actions
in the out-of-hospital market.
If Novartis China and Alibaba Health sign a strategic cooperation agreement, the two parties will upgrade their partnership, further deepen digital health cooperation in the fields of "cardiovascular and cerebrovascular, immunology, respiratory, oncology, and ophthalmology" with their respective advantages, and explore the full-link management mode
of patients.
It is understood that Alibaba Health and Novartis China have actually had in-depth business cooperation in a number of disease fields, and this cooperation upgrade will give full play to the advantages of both parties to jointly explore the "patient-centered" Internet medical and health service model and improve the quality
of life of patients.
At the Expo, Alibaba Health and Pfizer China also signed a strategic agreement on disease education innovation cooperation, on the basis of previous cooperation, the two parties will give full play to their respective advantages in the field of public health and health, explore the cooperation model of disease education and innovative drugs, and jointly develop digital health business
.
In addition, Organon and Ali Health also announced a strategic cooperation at the Expo to jointly explore the innovation of digital chronic disease management models, improve patients' compliance with diagnosis and treatment through digital patient management models, and help patients achieve more scientific full-cycle management
of chronic diseases.
In addition to Ali Health, Meituan is also working with many pharmacies and pharmaceutical companies to explore digital paths
.
It is understood that Meituan Buy Pharmacy recently announced that the Meituan Buy Drug Take-off Plan for chain pharmacy merchants will be upgraded to 3.
0, which will help pharmacies upgrade digitally through four major sectors and nine major measures; in terms of pharmaceutical companies, Meituan Buy Pharmaceutical has also launched a complete set of digital product matrix to help pharmaceutical companies develop online
from the dimensions of awareness, accessibility, payment, and compliance 。 In addition, on September 24, JD Health reached a strategic cooperation with Omron Health Medical, and the two parties announced that they will continue to provide consumers with more valuable products and services and promote the upgrading
of the national health management system through cooperation in health data interconnection, service model innovation, digital intelligence marketing and other fields.
Industry analysts believe that the commercialization pressure brought about by high R&D costs is forcing many pharmaceutical companies to accelerate R&D through digitalization, as well as make breakthroughs in the out-of-hospital market, shorten the time period for products to reach the market, improve the awareness rate of new products, and cover more patients
.
In this context, with the further deepening of the reform of the pharmaceutical system in the future, the development of digitalization of pharmaceutical enterprises is expected to continue to accelerate
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.